---
id: 128
title: Neisseria gonorrhoeae (Gonorrhea) and Resistance
category: organisms
subcategory: gram_negative_cocci
tags: [gonorrhea, GC, ceftriaxone, disseminated-gonococcal-infection, DGI]
difficulty: medium
---

## Question

How is gonorrhea treated given rising resistance? Use the **"Ceftriaxone 500mg IM × 1 (Only Reliable Agent)"** framework.

## Answer

### **Gonorrhea Treatment (2024 CDC Guidelines):**

**Uncomplicated Urogenital/Rectal/Pharyngeal:**
- **Ceftriaxone 500mg IM × 1 dose** (1g if weight >150kg)
- **PLUS** consider **doxycycline 100mg PO BID × 7 days** (empiric chlamydia coverage)

**Alternative (if ceftriaxone not available/feasible):**
- **Gentamicin 240mg IM × 1** + **azithromycin 2g PO × 1** (not preferred, resistance concerns)

**Pharyngeal Gonorrhea:**
- **Ceftriaxone 500mg IM × 1**
- **NO alternatives** (pharyngeal GC more difficult to eradicate)
- **Test of cure mandatory** at 7-14 days (NAAT)

### **Disseminated Gonococcal Infection (DGI):**

**Presentation:**
- **Triad:** **Tenosynovitis** (most common), **dermatitis** (pustular skin lesions), **polyarthralgia/arthritis**
- **Septic arthritis** (knee most common)
- **Rare:** Endocarditis, meningitis

**Treatment:**
- **Ceftriaxone 1g IV/IM daily** × 7 days (or 1-2 days after improvement → switch to oral)
- **Step-down:** **Cefixime 400mg PO BID** (if available and susceptible) to complete 7 days
- **Alternative:** Ceftriaxone 1g IV daily × 7 days (full course)

**Gonococcal Arthritis:**
- **Ceftriaxone 1g IV/IM daily** × 7-14 days
- **Drainage** of septic joint (arthrocentesis or surgical)

## Key Points

### **Resistance Evolution:**

| Era | Resistant to | Current Agent |
|-----|-------------|---------------|
| **1940s-1980s** | **Penicillin** (PPNG, chromosomal) | Switched to fluoroquinolones |
| **1990s-2000s** | **Fluoroquinolones** (widespread) | Switched to cephalosporins |
| **2010s** | **Azithromycin** (increasing) | Ceftriaxone ALONE now recommended |
| **2020s** | **Ceftriaxone** (rare but emerging) | **Last reliable option** |

**Current Situation:**
- **Ceftriaxone** = **only reliably effective agent**
- **Dual therapy** (ceftriaxone + azithromycin) **no longer recommended** routinely (azithromycin resistance)
- **FC431** and **zoliflodacin** = investigational new agents

### **When to Suspect Resistance:**

**Treatment Failure:**
- Persistent symptoms after treatment
- Positive test of cure (especially pharyngeal)

**High-Risk Exposures:**
- Travel to Asia (especially Southeast Asia, Western Pacific)
- Sex partners with treatment failure

### **Test of Cure:**

**Mandatory:**
- **Pharyngeal gonorrhea** (higher treatment failure rates)
- **Pregnant patients**
- **Persistent symptoms**
- **Suspected treatment failure**

**Timing:**
- **7-14 days after treatment** (NAAT)
- **Do NOT test earlier** (risk of false positive from dead organisms)

### **Screening and Reporting:**

**Screen:**
- **Sexually active women <25 years** (annual)
- **MSM** (every 3-12 months depending on risk)
- **Pregnant women** (first visit, 3rd trimester if high-risk)

**Report:**
- **Ceftriaxone treatment failures:** Report to CDC immediately

### **Special Populations:**

**Neonatal Conjunctivitis (Ophthalmia Neonatorum):**
- **Ceftriaxone 25-50 mg/kg IV/IM × 1 dose** (max 125mg)
- **Prevention:** Erythromycin 0.5% eye ointment at birth (standard of care)

**Pregnancy:**
- **Ceftriaxone 500mg IM × 1**
- **Avoid:** Fluoroquinolones, doxycycline

### **Clinical Pearls:**
- **Ceftriaxone 500mg IM × 1** = ONLY reliable treatment
- **Fluoroquinolones NO LONGER recommended** (widespread resistance)
- **Dual therapy (ceftriaxone + azithromycin) no longer routine**
- **DGI triad:** Tenosynovitis + dermatitis + polyarthralgia
- **Pharyngeal GC:** Test of cure mandatory (higher treatment failure)
- **Report treatment failures** to CDC
- **Emerging resistance** = major public health threat

## Sources

- [CDC: Gonorrhea Treatment Guidelines 2024]
- [NEJM: Antibiotic-Resistant Gonorrhea 2024]

## Media

N/A
